Literature DB >> 19952271

Mechanisms regulating repression of haptoglobin production by peroxisome proliferator-activated receptor-gamma ligands in adipocytes.

Cecile Vernochet1, Kathryn E Davis, Philipp E Scherer, Stephen R Farmer.   

Abstract

Obesity leads to inflammation of white adipose tissue involving enhanced secretion of cytokines and acute-phase proteins in response in part to the accumulation of excess lipids in adipocytes. Haptoglobin is an acute-phase reactant secreted by white adipose tissue and induced by inflammatory cytokines such as TNFalpha. In this study, we investigated the mechanisms regulating haptoglobin expression in adipocytes. Peroxisome proliferator-activated receptor (PPAR)-gamma agonists such as thiazolidinediones (TZDs) as well as non-TZD ligands can repress in vitro and in vivo haptoglobin expression in adipocytes and also prevent its induction by TNFalpha. This action requires direct involvement of PPAR gamma in regulating haptoglobin gene transcription because mutation of critical amino acids within helix 7 of the ligand-binding domain of PPAR gamma prevents repression of the haptoglobin gene by the synthetic ligands. Chromatin immunoprecipitation analysis shows active binding of PPAR gamma to a distal region of the haptoglobin promoter, which contains putative PPAR gamma binding sites. Additionally, PPAR gamma induces transcription of a luciferase reporter gene when driven by the distal promoter region of the haptoglobin gene, and TZD treatment significantly reduces the extent of this induction. Furthermore, the mutated PPAR gamma is incapable of enhancing luciferase activity in these in vitro reporter gene assays. In contrast to other adipokines repressed by TZDs such as resistin and chemerin, repression of haptoglobin does not require either CCAAT/enhancer-binding protein C/EBP alpha or the corepressors C-terminal binding protein 1 or 2. These data are consistent with a model in which synthetic PPAR gamma ligands selectively activate PPAR gamma bound to the haptoglobin gene promoter to arrest haptoglobin gene transcription.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19952271      PMCID: PMC2817616          DOI: 10.1210/en.2009-1057

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  27 in total

1.  Induction and regulation of acute phase proteins in transdifferentiated hepatocytes.

Authors:  Juliya K Kurash; Chia Ning Shen; David Tosh
Journal:  Exp Cell Res       Date:  2004-01-15       Impact factor: 3.905

2.  A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes.

Authors:  Irina Kratchmarova; Dario E Kalume; Blagoy Blagoev; Philipp E Scherer; Alexandre V Podtelejnikov; Henrik Molina; Perry E Bickel; Jens S Andersen; Minerva M Fernandez; Jacob Bunkenborg; Peter Roepstorff; Karsten Kristiansen; Harvey F Lodish; Matthias Mann; Akhilesh Pandey
Journal:  Mol Cell Proteomics       Date:  2002-03       Impact factor: 5.911

3.  Acute-phase protein haptoglobin is a cell migration factor involved in arterial restructuring.

Authors:  Dominique P V de Kleijn; Mirjam B Smeets; Patrick P C W Kemmeren; Sai K Lim; Ben J Van Middelaar; Evelyn Velema; Arjan Schoneveld; Gerard Pasterkamp; Cornelius Borst
Journal:  FASEB J       Date:  2002-05-21       Impact factor: 5.191

4.  Involvement of CCAAT/enhancer-binding protein alpha in haptoglobin gene expression by all-trans-retinoic acid.

Authors:  Il-Ha Lee; Jeong-Hwa Lee; Myung-Jae Lee; Soo-Young Lee; In-Sook Kim
Journal:  Biochem Biophys Res Commun       Date:  2002-06-28       Impact factor: 3.575

5.  Haptoglobin and risk of myocardial infarction, stroke, and congestive heart failure in 342,125 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).

Authors:  Ingar Holme; Are H Aastveit; Niklas Hammar; Ingmar Jungner; Göran Walldius
Journal:  Ann Med       Date:  2009       Impact factor: 4.709

6.  Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function.

Authors:  Andrew N Carley; Lisa M Semeniuk; Yakhin Shimoni; Ellen Aasum; Terje S Larsen; Joel P Berger; David L Severson
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-11-04       Impact factor: 4.310

7.  Phosphorylation of C/EBPbeta at a consensus extracellular signal-regulated kinase/glycogen synthase kinase 3 site is required for the induction of adiponectin gene expression during the differentiation of mouse fibroblasts into adipocytes.

Authors:  Bae-Hang Park; Li Qiang; Stephen R Farmer
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

8.  Regulation of haptoglobin gene expression in 3T3-L1 adipocytes by cytokines, catecholamines, and PPARgamma.

Authors:  Claudia Oller do Nascimento; Leif Hunter; Paul Trayhurn
Journal:  Biochem Biophys Res Commun       Date:  2004-01-16       Impact factor: 3.575

9.  Obesity modulates the expression of haptoglobin in the white adipose tissue via TNFalpha.

Authors:  Chiara Chiellini; Anna Bertacca; Silvia E Novelli; Cem Z Görgün; Annamaria Ciccarone; Antonio Giordano; Haiyan Xu; Alexander Soukas; Mario Costa; Daniele Gandini; Roberto Dimitri; Pietro Bottone; Paolo Cecchetti; Ennia Pardini; Lucia Perego; Renzo Navalesi; Franco Folli; Luca Benzi; Saverio Cinti; Jeffrey M Friedman; Gökhan S Hotamisligil; Margherita Maffei
Journal:  J Cell Physiol       Date:  2002-02       Impact factor: 6.384

10.  Serum haptoglobin: a novel marker of adiposity in humans.

Authors:  C Chiellini; F Santini; A Marsili; P Berti; A Bertacca; C Pelosini; G Scartabelli; E Pardini; J López-Soriano; R Centoni; A M Ciccarone; L Benzi; P Vitti; S Del Prato; A Pinchera; M Maffei
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

View more
  8 in total

1.  PPARγ agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein.

Authors:  Haruya Ohno; Kosaku Shinoda; Bruce M Spiegelman; Shingo Kajimura
Journal:  Cell Metab       Date:  2012-03-07       Impact factor: 27.287

2.  Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: adipose depot specificity and gender dimorphism.

Authors:  Assim A Alfadda; Reem M Sallam; Muhammad Azhar Chishti; Amr S Moustafa; Sumbul Fatma; Waleed S Alomaim; Mohammed Y Al-Naami; Abdulelah F Bassas; George P Chrousos; Hyunsun Jo
Journal:  Mol Cells       Date:  2012-04-27       Impact factor: 5.034

3.  Myocardin-related transcription factor A regulates conversion of progenitors to beige adipocytes.

Authors:  Meghan E McDonald; Chendi Li; Hejiao Bian; Barbara D Smith; Matthew D Layne; Stephen R Farmer
Journal:  Cell       Date:  2015-01-08       Impact factor: 41.582

4.  Proximal tubule haptoglobin gene activation is an integral component of the acute kidney injury "stress response".

Authors:  Richard A Zager; Anitha Vijayan; Ali C M Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-09

5.  Bioactivity-guided fractionation of the triglyceride-lowering component and in vivo and in vitro evaluation of hypolipidemic effects of Calyx seu Fructus Physalis.

Authors:  Yihui Yang; Xianmei Piao; Mingyu Zhang; Xiaodan Wang; Bing Xu; Jiuxin Zhu; Zhiwei Fang; Yunlong Hou; Yanjie Lu; Baofeng Yang
Journal:  Lipids Health Dis       Date:  2012-03-14       Impact factor: 3.876

6.  Chemerin and adiponectin contribute reciprocally to metabolic syndrome.

Authors:  Sang Hui Chu; Mi Kyung Lee; Ki Yong Ahn; Jee-Aee Im; Min Soo Park; Duk-Chul Lee; Justin Y Jeon; Ji Won Lee
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

7.  Level of dietary energy and 2,4-thiazolidinedione alter molecular and systemic biomarkers of inflammation and liver function in Holstein cows.

Authors:  Afshin Hosseini; Mustafa Salman; Zheng Zhou; James K Drackley; Erminio Trevisi; Juan J Loor
Journal:  J Anim Sci Biotechnol       Date:  2017-08-01

8.  Evidence for three genetic loci involved in both anorexia nervosa risk and variation of body mass index.

Authors:  A Hinney; M Kesselmeier; S Jall; A-L Volckmar; M Föcker; J Antel; I M Heid; T W Winkler; S F A Grant; Y Guo; A W Bergen; W Kaye; W Berrettini; H Hakonarson; B Herpertz-Dahlmann; M de Zwaan; W Herzog; S Ehrlich; S Zipfel; K M Egberts; R Adan; M Brandys; A van Elburg; V Boraska Perica; C S Franklin; M H Tschöp; E Zeggini; C M Bulik; D Collier; A Scherag; T D Müller; J Hebebrand
Journal:  Mol Psychiatry       Date:  2016-05-17       Impact factor: 13.437

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.